---
category: news
title: "CTAD Lessons for 2020: More Phase 2 Trials, More Diversity"
excerpt: "What lies ahead for Alzheimer’s therapy development? While anti-amyloid antibodies are at last signaling ... Nicolai Franzmeier of Ludwig Maximilians University, Germany, believes so. He used artificial intelligence to analyze multiple biomarkers, including structural MRI, FDG PET, amyloid PET, and cerebrospinal fluid Aβ/t-tau/p-tau, from ..."
publishedDateTime: 2020-01-10T03:06:00Z
sourceUrl: https://www.alzforum.org/news/conference-coverage/ctad-lessons-2020-more-phase-2-trials-more-diversity
type: article
quality: 24
heat: 24
published: false

provider:
  name: ALZFORUM
  domain: alzforum.org

topics:
  - AI
  - AI in Healthcare

images:
  - url: https://www.alzforum.org/sites/default/files/styles/media-medium/public/01.09_Masliah_CTAD_med.jpg?itok=Ht5m_dFb
    width: 380
    height: 292
    title: "CTAD Lessons for 2020: More Phase 2 Trials, More Diversity"

secured: "BD9cplD5U9H44zTvrznSJEdwzdSNN3veb3j1sFAeFjWoM4mTcaPQ/dnVRoD4/nQll0Ux7SRA5zPzziNtaWRpS3C66LdGX4S4oLQlPLE8YQKLL8OFYHonnG9PINhoeR5uL+AfBMoOCL4m+qUsyANlk2qU/ktZVy+TiIVUFZBTv5fhgW8ofpNcxc2hEh91kCzzqqaHXa8TV8oB4NFSW1RRo6CFdd1mFTZY2wCTPZLkwzuFYSuyaEGYlb0C/VpGNqk4dVkit9w5vdd4iMYBulQIytT4xN8zuRDwqaHw2JnCGHU=;fVxp4ySD8kxaBaVlJv3P+A=="
---

